Brief Summary
The aims of this clinical trial are (1) to assess the safety of AWT020 at different dosethe amount of medication taken levels; (2) to determine the pharmacokinetics and pharmacodynamics of AWT020 in subjects with locally advancedat a late stage, far along or metastatic cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs who have failed standard therapy.
Intervention / Treatment
- Biological: AWT020
Inclusion Criteria:
- Subject has provided informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment. prior to initiation of any study specific activities or procedures.
- Subject must be ≥ 18 years of age or per local regulation.
- Subjects must have a histological diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of solid tumors (carcinomacancer arising from tissues that line organs or sarcomacancer arising from bones and/or soft tissue) or malignantcancerous, may grow and spread to other areas of the body lymphomacancers of the lymphatic system, either progressive locally advanced not amenable to local therapy or metastatic, which is refractory, ineligible (in the opinion of the Investigator) or intolerant to standard therapy. Subjects with hepatocellular carcinoma must be diagnosed with dynamic CT or MRI if no tissuea group of cells that work together to perform a function diagnosis is available.
- Subject must have performance status of 0, or 1 on the ECOG performance scale.
- Subject with adequate organ function.
- Life expectancy is longer than three months.
- Subject must be able to receive effective contraceptive measures.